Stay updated with breaking news from Drug Pricing Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A study by the UC Berkeley School of Public Health revealed that hospitals enact significant price increases and retain large sums of insurer payments on cancer and other specialty drugs.
Results Reflect Continued Strength of In-Line and New Products, Pipeline Execution and Business Development Activity, Supporting Growth Momentum into 2024 Reports Fourth Quarter Revenues of...
Estes Park Health reflects on 2023 accomplishments at Jan. board meeting
A bipartisan group of senators Feb. 2 released for stakeholder feedback a discussion draft of legislation to clarify in statute Congress’ intent for the 340B program to help safety net providers maintain, improve and expand patient access to health care services by requiring drug manufacturers that participate in Medicaid and Medicare Part B to provide discounts and rebates to covered entities that serve a disproportionate share of low-income and underserved patients.
UMN researchers describe the misuse of 340B benefits among larger public health entities.